{"id":"gemigliptin-and-or-rosuvastatin","safety":{"commonSideEffects":[{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Hypoglycemia"}]},"_chembl":{"chemblId":"CHEMBL1744447","moleculeType":"Small molecule","molecularWeight":"1001.15"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a fixed-dose combination where gemigliptin enhances insulin secretion and reduces glucagon by preventing the degradation of GLP-1 and GIP, addressing hyperglycemia in type 2 diabetes. Rosuvastatin simultaneously reduces LDL cholesterol and cardiovascular risk by inhibiting the rate-limiting enzyme in cholesterol synthesis. The combination addresses both glycemic and lipid management in patients with type 2 diabetes and dyslipidemia.","oneSentence":"Gemigliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and improve glycemic control, while rosuvastatin inhibits HMG-CoA reductase to lower cholesterol.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:13:52.641Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus with dyslipidemia"}]},"trialDetails":[{"nctId":"NCT02126358","phase":"PHASE3","title":"Gemigliptin-Rosuvastatin Fix-dose Combination Phase 3(BALANCE)","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2014-05","conditions":"Type 2 Diabetes, Dyslipidemia","enrollment":290}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5132,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Gemigliptin and/or Rosuvastatin","genericName":"Gemigliptin and/or Rosuvastatin","companyName":"LG Life Sciences","companyId":"lg-life-sciences","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Gemigliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and improve glycemic control, while rosuvastatin inhibits HMG-CoA reductase to lower cholesterol. Used for Type 2 diabetes mellitus with dyslipidemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}